【摘要】：目的： 中醫(yī)藥老字號是我國文明歷史的智慧結(jié)晶,是民族中藥工商業(yè)百年沉淀的獨特標(biāo)識,具有深厚的歷史印記與民族特色,已經(jīng)成為了當(dāng)今社會寶貴的物質(zhì)和文化遺產(chǎn),但在現(xiàn)實中,有大部分的中藥老字號因為流失或經(jīng)營不善而消失,能存活下來的中藥老字號品牌較少,而有條件進(jìn)入國內(nèi)資本市場的中藥老字號企業(yè)更是少之又少,本文研究的目的是探討這些有著中藥老字號輝煌品牌光環(huán)的上市公司的經(jīng)營績效與現(xiàn)狀,研究其經(jīng)營績效的綜合排名,取長補短,有利于提高中華老字號醫(yī)藥類上市公司的經(jīng)營管理能力,弘揚中華文化,保護(hù)民族品牌。 方法： 本文通過文獻(xiàn)分析法等對國內(nèi)中華老字號、經(jīng)營績效的相關(guān)理論進(jìn)行回顧與歸納,建立了十三個績效指標(biāo)的評價體系,并采用主成分分析法對國內(nèi)A股資本市場上中藥老字號企業(yè)2012年的經(jīng)營數(shù)據(jù)進(jìn)行分析得出其綜合排名。 結(jié)果： 本文收集的19家研究樣本的數(shù)據(jù)通過了KMO檢驗適合做主成分分析,得出2012年中華老字號醫(yī)藥類上市公司經(jīng)營績效的排名及各主成分排名,其中太安堂在2012年中經(jīng)營績效排名第一,開開實業(yè)排名第19；在盈利能力、償債、營運、成長發(fā)展能力方面,排名第一的分別是云南白藥、東阿阿膠、廣州藥業(yè)、太安堂。結(jié)論： 通過本文的研究,得出以下結(jié)論：有八家中華老字號醫(yī)藥上市公司的綜合經(jīng)營績效明顯高于其余幾家；在2012年中,中華老字號醫(yī)藥類上市公司經(jīng)營績效整體較好；中華老字號醫(yī)藥類上市公司的綜合效益差距不大；部分中華老字號在上市公司的運作中表現(xiàn)不佳。
[Abstract]:Objective: the traditional Chinese medicine brand is the wisdom crystallization of the civilization history of our country, is the unique symbol of the Chinese medicine industry and commerce precipitate for a hundred years, has the profound historical imprint and the national characteristic. It has become a valuable material and cultural heritage in today's society, but in reality, most of the old Chinese medicine brands have disappeared because of loss or poor management, and there are fewer brands of old Chinese medicine brands that can survive. However, there are few traditional Chinese medicine enterprises which have the condition to enter the domestic capital market. The purpose of this paper is to discuss the management performance and present situation of these listed companies with the glorious brand of traditional Chinese medicine. To study the comprehensive ranking of its management performance and to learn from each other is helpful to improve the management and management ability of the listed Chinese medicine companies, to carry forward the Chinese culture and to protect the national brands. Methods: based on the literature analysis method, this paper reviews and summarizes the relevant theories of China's old brand and management performance, and establishes the evaluation system of thirteen performance indicators. The main component analysis method is used to analyze the management data of the traditional Chinese medicine enterprises in the domestic A share capital market in 2012, and the comprehensive ranking is obtained. Results: the data of 19 research samples collected in this paper are suitable for principal component analysis through KMO test, and the ranking of operating performance and principal components of Chinese famous pharmaceutical listed companies in 2012 is obtained. Taiantang in 2012 in terms of operating performance ranked first, open industry ranked No. 19; In the profitability, debt service, operation, growth and development capacity, ranked first are Yunnan Baiyao, Donga Ejiao, Guangzhou Pharmaceutical Industry, Taiantang. Conclusion: through the research of this paper, the following conclusions can be drawn: there are eight famous Chinese medicine listed companies' comprehensive operating performance is obviously higher than the others, in the middle of 2012, the Chinese traditional medicine listed companies' overall operating performance is better; There is not much difference in the comprehensive benefit of the old Chinese medicine listed companies, and some of the old Chinese brands are not performing well in the operation of the listed companies.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：F272.5;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 冷志明;“中華老字號”品牌發(fā)展滯后原因及其對策研究[J];北京工商大學(xué)學(xué)報(社會科學(xué)版);2004年01期

2 王海波;;企業(yè)績效評價存在的問題及對策[J];財經(jīng)界(學(xué)術(shù)版);2009年11期

3 茅靜朦;;醫(yī)藥上市公司經(jīng)營業(yè)績評價體系設(shè)計[J];財會通訊;2012年35期

4 俞文強;朱春華;;基于SPSS下主成分分析中若干問題的總結(jié)[J];高等函授學(xué)報(自然科學(xué)版);2013年02期

5 楊帆;中華“老字號”的發(fā)展戰(zhàn)略分析[J];環(huán)渤海經(jīng)濟w，

本文編號：2377944